LDL cholesterol is one of the most important heart-risk measurements I review in patients with diabetes. But there is no longer one universal LDL target for every person with diabetes. Your age, blood pressure, smoking history, kidney health, previous heart attack or stroke, and overall cardiovascular risk determine how intensively LDL should be treated.
LDL stands for low-density lipoprotein. Cholesterol cannot travel through blood by itself, so lipoprotein particles carry it between the liver and other tissues.
When too many LDL-containing particles remain in the bloodstream, they can enter the artery wall. Cholesterol may then accumulate as part of an inflammatory plaque. Over time, plaque can narrow the artery or rupture and trigger a clot, causing a heart attack or ischemic stroke.
Diabetes affects more than blood glucose. High glucose, insulin resistance, high blood pressure, kidney disease, inflammation, smoking, and abnormal blood lipids can work together to injure blood vessels and accelerate atherosclerosis.
Many people with type 2 diabetes have a pattern that includes:
This is why a person with diabetes may benefit from LDL-lowering medicine even when the LDL result would not have seemed alarming by older standards. Managing type 2 diabetes should include glucose, cholesterol, blood pressure, kidney health, weight, activity, and smoking—not glucose alone.
I often tell patients that the correct question is not only, “What is my LDL?” It is also, “What is my cardiovascular risk, and how much should my LDL be lowered?”
| Clinical situation | Common current approach | LDL goal or response |
|---|---|---|
| Diabetes, age 40–75, without known ASCVD | Moderate-intensity statin is generally recommended in addition to lifestyle treatment. | The exact LDL goal depends on the complete risk assessment. |
| Diabetes, age 40–75, with higher cardiovascular risk | High-intensity statin is generally recommended. Additional risk factors may include older age, hypertension, smoking, chronic kidney disease, obesity, or other major risks. | Reduce LDL by at least 50% and aim for below 70 mg/dL (below 1.8 mmol/L). |
| Diabetes with established ASCVD | High-intensity or maximally tolerated statin. Additional LDL-lowering medicine may be needed. | Reduce LDL by at least 50% and aim for below 55 mg/dL (below 1.4 mmol/L). |
| Diabetes, age 20–39, with additional risk factors | A statin may be reasonable after discussion of benefits, long-term risk, pregnancy plans, and preferences. | Individualized. |
| Diabetes, age over 75 | Continuing a tolerated statin is often reasonable. Starting one should follow a discussion of benefit, frailty, medicines, life expectancy, and preferences. | Individualized. |
ASCVD means atherosclerotic cardiovascular disease. It includes previous heart attack, acute coronary syndrome, coronary or other arterial revascularization, ischemic stroke, transient ischemic attack caused by atherosclerosis, or peripheral artery disease.
| LDL in mg/dL | Approximate mmol/L | Common context |
|---|---|---|
| 55 mg/dL | 1.4 mmol/L | Common secondary-prevention goal in diabetes with ASCVD. |
| 70 mg/dL | 1.8 mmol/L | Common goal for higher-risk primary prevention. |
| 100 mg/dL | 2.6 mmol/L | May be acceptable in some lower-risk settings but is not a universal diabetes goal. |
| 190 mg/dL | 4.9 mmol/L | Very high; needs prompt medical evaluation, including consideration of familial hypercholesterolemia. |
To convert LDL from mg/dL to mmol/L, multiply by approximately 0.0259. These numbers are educational guides; your clinician may recommend a different goal.
The main treatment target in many guidelines because lowering LDL reduces heart attack and stroke risk.
Higher HDL is often associated with lower risk, but medicines are not prescribed simply to raise HDL. Lifestyle and total cardiovascular risk matter more.
Often rise with insulin resistance, high glucose, alcohol, excess calories, kidney disease, thyroid disease, and some medicines. Levels of 500 mg/dL or higher need prompt review because pancreatitis risk can increase.
These can help estimate the total burden of atherogenic particles, especially when triglycerides are high or LDL may underestimate risk.
The 2026 ACC/AHA dyslipidemia guidance also supports measuring lipoprotein(a), or Lp(a), at least once in adulthood. Lp(a) is largely inherited and may reveal additional risk that is not obvious from LDL alone.
A lipid panel is usually checked before starting or changing cholesterol treatment. Once a statin is started, LDL is commonly reassessed:
The repeat test helps your clinician confirm that the medicine is being taken, estimate the percentage LDL reduction, check whether the goal was reached, and decide whether another treatment is needed. A fasting sample is not always required, although fasting may be requested when triglycerides are very high or a calculated result is uncertain.
Lifestyle treatment is essential whether or not you take medicine. I recommend focusing on changes that improve cholesterol, glucose, blood pressure, and overall cardiovascular health together.
For a complete eating plan, see the cholesterol and diabetes diet guide and our diabetes plate-method meal plan.
Statins reduce cholesterol production in the liver, increase removal of LDL from the blood, and lower the risk of heart attack and stroke. They remain the first-line medicine for most adults with diabetes who need LDL-lowering treatment.
The specific drug and dose depend on age, kidney and liver health, interactions, previous side effects, pregnancy plans, and the amount of LDL reduction needed.
If LDL remains above goal on the maximally tolerated statin, or a patient cannot tolerate an effective statin dose, the clinician may consider:
Do not choose a medicine from an online list. Treatment should reflect your complete cardiovascular risk, current medicines, liver and kidney health, cost, access, and pregnancy status.
Statins can slightly increase blood glucose in some people. However, for patients who need a statin, the reduction in heart attack and stroke risk generally outweighs this small glucose effect. Having diabetes is not a reason to avoid an indicated statin.
Possible side effects may include muscle aches, weakness, digestive symptoms, or liver-test changes. Severe muscle injury is uncommon. If symptoms appear:
High LDL usually causes no symptoms and is not diagnosed by how you feel. However, seek urgent medical help for possible heart attack or stroke symptoms, including:
Also arrange timely medical evaluation if LDL is around 190 mg/dL or higher, if several close relatives had early heart attacks or strokes, or if you have tendon swellings or another possible sign of familial hypercholesterolemia.
It may be appropriate for some lower-risk people, but it is not the universal goal. Higher-risk adults with diabetes often aim below 70 mg/dL, while people with established ASCVD generally aim below 55 mg/dL.
Statin decisions are based on the chance of a future heart attack or stroke, not only the starting LDL number. Diabetes, age, blood pressure, kidney disease, smoking, and established artery disease may make treatment beneficial even when LDL appears moderate.
Sometimes lifestyle changes are sufficient for a lower-risk person, but they do not reliably replace statins in people for whom medication is recommended. Lifestyle and medicine work together.
Statins may cause a small rise in glucose in some people, but their cardiovascular benefits usually outweigh this effect when treatment is indicated. Continue monitoring glucose and discuss any change with your clinician.
No supplement has been shown to provide the same predictable cardiovascular protection as indicated statin therapy. Red yeast rice products can contain statin-like compounds in uncertain amounts and may cause similar interactions or side effects. Discuss every supplement with your doctor or pharmacist.
Contact the prescribing clinician rather than stopping permanently. Many patients can tolerate a different statin, dose, or schedule, sometimes combined with a non-statin medicine. Severe pain, marked weakness, or dark urine needs prompt medical review.